Key Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Players:
- AstraZeneca PLC
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Eli Lilly & Company
- Galmed Pharmaceuticals Ltd.
- GENFIT S.A.
- Novo Nordisk A/S
- Novartis AG
- PFIZER INC.
- Siemens Healthineers AG
- TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Zydus Lifesciences Limited
The presence of major players such as AstraZeneca PLC, Eli Lilly & Company, Galmed Pharmaceuticals Ltd., Pfizer Inc., Genfit SA, Novo Nordisk A/S, Takeda Pharmaceutical Company Ltd., and Arcturus Therapeutics Inc. contributes to the highly competitive nature of the non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market. These players are pushing the boundaries of innovation, making sizeable investments in research and development to study new mechanisms and treatment options. Furthermore, strategic partnerships and collaborations enable these firms to consolidate resources, tap advanced technologies, and extend services to new markets.
In May 2024, SomaLogic entered into a license agreement with OncoHost to develop precision cancer diagnostics, leveraging SomaLogic's proteomics platform. While primarily focused on oncology, the technologies developed may have applications in other diseases, including NASH, by identifying relevant protein biomarkers. This milestone underlines how clinical progress, together with supportive regulatory initiatives, has reshaped the market, urging players to stay innovative in order to expand and thrive in the competition.
Here are some leading companies in the NASH therapeutics and diagnostics market:
